RJFSA
TAK icon

Raymond James Financial Services Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$364K Buy
25,585
+4,937
+24% +$70K ﹤0.01% 2840
2024
Q2 		$267K Sell
20,648
-5,473
-21% -$72.5K ﹤0.01% 2946
2024
Q1 		$363K Sell
26,121
-10,278
-28% -$149K ﹤0.01% 2731
2023
Q4 		$519K Sell
36,399
-9,229
-20% -$131K ﹤0.01% 2383
2023
Q3 		$706K Sell
45,628
-22,688
-33% -$351K ﹤0.01% 2115
2023
Q2 		$1.07M Sell
68,316
-1,281
-2% -$21K ﹤0.01% 1891
2023
Q1 		$1.15M Sell
69,597
-824
-1% -$13.1K ﹤0.01% 1822
2022
Q4 		$1.1M Sell
70,421
-87,325
-55% -$1.22M ﹤0.01% 1780
2022
Q3 		$2.05M Sell
157,746
-5,428
-3% -$75.5K ﹤0.01% 1410
2022
Q2 		$2.29M Buy
163,174
+7,712
+5% +$110K 0.01% 1365
2022
Q1 		$2.23M Buy
155,462
+8,624
+6% +$127K ﹤0.01% 1420
2021
Q4 		$2M Sell
146,838
-33,203
-18% -$466K ﹤0.01% 1534
2021
Q3 		$2.95M Buy
180,041
+7,913
+5% +$133K 0.01% 1260
2021
Q2 		$2.9M Buy
172,128
+25,074
+17% +$427K 0.01% 1262
2021
Q1 		$2.69M Buy
147,054
+74,856
+104% +$1.35M 0.01% 1228
2020
Q4 		$1.31M Buy
72,198
+19,315
+37% +$339K ﹤0.01% 1540
2020
Q3 		$943K Buy
52,883
+2,707
+5% +$49.3K ﹤0.01% 1586
2020
Q2 		$900K Buy
50,176
+23,093
+85% +$415K ﹤0.01% 1558
2020
Q1 		$411K Buy
27,083
+10,573
+64% +$192K ﹤0.01% 1665
2019
Q4 		$326K Sell
16,510
-1,716
-9% -$32.8K ﹤0.01% 2272
2019
Q3 		$313K Sell
18,226
-5,960
-25% -$103K ﹤0.01% 2222
2019
Q2 		$428K Sell
24,186
-1,718
-7% -$31.3K ﹤0.01% 2028
2019
Q1 		$528K Buy
+25,904
New +$521K ﹤0.01% 1868

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Raymond James Financial Services Advisors's TAK Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Takeda Pharmaceutical (TAK) stake by 24% in Q3 2024, buying an estimated $70K and bringing the position to 25,585 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Raymond James Financial Services Advisors first reported a position in TAK in Q1 2019 and has held it in 23 quarters since. The position peaked at $2.95M in Q3 2021. 299 funds tracked by Wall St. Rank hold TAK as of Q3 2024.

  • Raymond James Financial Services Advisors held 25,585 shares of Takeda Pharmaceutical worth $364K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 4,937 Takeda Pharmaceutical shares in Q3 2024, an estimated $70K.
  • Takeda Pharmaceutical made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2840 holding.
  • Raymond James Financial Services Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 23 quarters since.
  • Raymond James Financial Services Advisors's Takeda Pharmaceutical position peaked at $2.95M in Q3 2021.
  • 299 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.